Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study (Q38670952)
Jump to navigation
Jump to search
scientific article published on 04 December 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study |
scientific article published on 04 December 2015 |
Statements
1 reference
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study (English)
1 reference
Mats Jerkeman
1 reference
Martin Dreyling
1 reference
Rodrigo Santucci Silva
1 reference
Chiara Rusconi
1 reference
Fritz Offner
1 reference
Dolores Caballero
1 reference
Georg Hess
1 reference
Isabelle Bence-Bruckler
1 reference
Seok-Goo Cho
1 reference
John Bothos
1 reference
Jenna D Goldberg
1 reference
Christopher Enny
1 reference
Shana Traina
1 reference
Sriram Balasubramanian
1 reference
Nibedita Bandyopadhyay
1 reference
Steven Sun
1 reference
Jessica Vermeulen
1 reference
Aleksandra Rizo
1 reference
Simon Rule
1 reference
4 December 2015
1 reference
1 reference
Identifiers
1 reference